ASPET’s Journal of Pharmacology and Experimental Therapeutics is planning a new special section titled “Novel Targeted Therapies for Advanced Prostate Cancer” to be published July 1, 2025.
This special section calls for original research on innovative and impactful research in therapeutics and disease mechanisms for advanced prostate cancer. The scope encompasses basic, translational, preclinical, as well as clinical research, designated for understanding and developing treatments for advanced prostate cancer. Original research articles and mini reviews will be accepted.
Prospective topics can include:
- Discovery of novel targets and/or therapeutics agents
- Development of single or combination treatments
- Immune checkpoint inhibitors and combinations
- Improved delivery and optimization of current therapies
- Repurposed pharmacological agents
- Investigation of drug mechanisms and potential therapeutic targets
Article proposals, including the title, abstract, significance statement and full author information, should be submitted as a pre-submission inquiry to the Journal of Pharmacology and Experimental Therapeutics. Special section guest editors Drs. Qiming Jane Wang and Ming Chen will review the proposals for approval and respond to the authors with comments and suggestions, before submission of the full article.
The submission deadline is February 1, 2025, and all submissions must refer to the journal’s Instructions to Authors.